Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 13 | 2016 | 1077 | 0.640 |
Why?
|
| Head and Neck Neoplasms | 14 | 2017 | 1073 | 0.580 |
Why?
|
| Tongue Diseases | 1 | 2016 | 9 | 0.490 |
Why?
|
| Ossification, Heterotopic | 1 | 2016 | 32 | 0.480 |
Why?
|
| Choristoma | 1 | 2016 | 59 | 0.480 |
Why?
|
| Mouth Neoplasms | 4 | 2010 | 202 | 0.340 |
Why?
|
| Oropharynx | 2 | 2016 | 14 | 0.250 |
Why?
|
| Laryngeal Neoplasms | 3 | 2017 | 89 | 0.240 |
Why?
|
| Tumor Virus Infections | 2 | 2014 | 83 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2011 | 1448 | 0.230 |
Why?
|
| Trachea | 2 | 2017 | 245 | 0.230 |
Why?
|
| Papillomaviridae | 2 | 2014 | 179 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2011 | 2544 | 0.220 |
Why?
|
| Chemoradiotherapy | 4 | 2017 | 326 | 0.200 |
Why?
|
| Photochemotherapy | 2 | 1995 | 100 | 0.200 |
Why?
|
| Larynx | 3 | 2017 | 35 | 0.200 |
Why?
|
| Papillomavirus Infections | 2 | 2014 | 300 | 0.190 |
Why?
|
| Genes, p53 | 4 | 1998 | 108 | 0.180 |
Why?
|
| Nasal Obstruction | 2 | 1997 | 21 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1053 | 0.160 |
Why?
|
| Salvage Therapy | 1 | 2000 | 235 | 0.140 |
Why?
|
| Combined Modality Therapy | 10 | 2016 | 1723 | 0.140 |
Why?
|
| Tonsillar Neoplasms | 1 | 1997 | 6 | 0.140 |
Why?
|
| Adult | 21 | 2017 | 27918 | 0.130 |
Why?
|
| Glottis | 1 | 2017 | 13 | 0.130 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2016 | 188 | 0.130 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2017 | 24 | 0.130 |
Why?
|
| Nasal Cavity | 1 | 1997 | 91 | 0.130 |
Why?
|
| Carcinoma | 2 | 2016 | 439 | 0.130 |
Why?
|
| Otolaryngology | 1 | 1997 | 55 | 0.120 |
Why?
|
| Punctures | 1 | 1996 | 28 | 0.120 |
Why?
|
| Tolonium Chloride | 1 | 1996 | 5 | 0.120 |
Why?
|
| Laryngeal Diseases | 2 | 2011 | 20 | 0.120 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2016 | 46 | 0.120 |
Why?
|
| Lymph Nodes | 4 | 2016 | 548 | 0.120 |
Why?
|
| Hypopharynx | 1 | 1996 | 9 | 0.120 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 1996 | 15 | 0.120 |
Why?
|
| Esophagus | 1 | 1996 | 113 | 0.120 |
Why?
|
| Respiration | 1 | 1997 | 269 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2017 | 236 | 0.110 |
Why?
|
| Female | 24 | 2017 | 48698 | 0.110 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 1994 | 15 | 0.110 |
Why?
|
| Epistaxis | 1 | 1994 | 19 | 0.110 |
Why?
|
| Neoplasm Staging | 7 | 2016 | 2017 | 0.110 |
Why?
|
| Humans | 34 | 2017 | 93511 | 0.110 |
Why?
|
| Exercise | 1 | 1997 | 353 | 0.100 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 1996 | 149 | 0.100 |
Why?
|
| Nasal Mucosa | 1 | 1994 | 193 | 0.100 |
Why?
|
| Uterine Cervicitis | 1 | 1993 | 4 | 0.100 |
Why?
|
| Hydroxyurea | 7 | 2011 | 231 | 0.100 |
Why?
|
| Middle Aged | 20 | 2016 | 27569 | 0.100 |
Why?
|
| Syncope | 1 | 1993 | 29 | 0.100 |
Why?
|
| Follow-Up Studies | 8 | 2011 | 3828 | 0.100 |
Why?
|
| Male | 24 | 2017 | 44553 | 0.100 |
Why?
|
| Fluorouracil | 7 | 2011 | 524 | 0.090 |
Why?
|
| Prognosis | 8 | 2016 | 3910 | 0.090 |
Why?
|
| Aged | 15 | 2016 | 20430 | 0.090 |
Why?
|
| Skin Neoplasms | 2 | 1995 | 620 | 0.090 |
Why?
|
| Vocal Cords | 1 | 2011 | 26 | 0.090 |
Why?
|
| Cumulative Trauma Disorders | 1 | 2011 | 19 | 0.090 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2011 | 81 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 572 | 0.080 |
Why?
|
| Radiotherapy Dosage | 5 | 2011 | 472 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2011 | 245 | 0.070 |
Why?
|
| Airway Obstruction | 3 | 1999 | 113 | 0.070 |
Why?
|
| Genomics | 1 | 2014 | 848 | 0.070 |
Why?
|
| Disease-Free Survival | 5 | 2011 | 1170 | 0.070 |
Why?
|
| Laryngectomy | 2 | 2017 | 26 | 0.060 |
Why?
|
| Survival Rate | 5 | 2003 | 1948 | 0.060 |
Why?
|
| Paclitaxel | 5 | 2011 | 479 | 0.060 |
Why?
|
| Treatment Outcome | 8 | 2011 | 9098 | 0.050 |
Why?
|
| Tongue Neoplasms | 2 | 2010 | 51 | 0.050 |
Why?
|
| Neck Dissection | 1 | 2004 | 67 | 0.050 |
Why?
|
| Retrospective Studies | 7 | 2011 | 10164 | 0.050 |
Why?
|
| Induction Chemotherapy | 2 | 2016 | 146 | 0.050 |
Why?
|
| Remission Induction | 3 | 2016 | 738 | 0.050 |
Why?
|
| Alcohol Drinking | 2 | 2011 | 283 | 0.040 |
Why?
|
| Goiter, Nodular | 1 | 2001 | 7 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2011 | 7061 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2016 | 1524 | 0.040 |
Why?
|
| Parathyroid Neoplasms | 1 | 2001 | 60 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2001 | 137 | 0.040 |
Why?
|
| Mutation | 3 | 2014 | 4272 | 0.040 |
Why?
|
| Smoking | 2 | 2011 | 648 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2000 | 242 | 0.040 |
Why?
|
| Crack Cocaine | 1 | 1999 | 2 | 0.040 |
Why?
|
| Adenoma | 1 | 2001 | 258 | 0.040 |
Why?
|
| Inhalation | 1 | 1999 | 34 | 0.040 |
Why?
|
| Cocaine-Related Disorders | 1 | 1999 | 40 | 0.040 |
Why?
|
| Nebulizers and Vaporizers | 1 | 1999 | 62 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2011 | 4560 | 0.040 |
Why?
|
| Foreign Bodies | 1 | 1999 | 63 | 0.030 |
Why?
|
| Cysts | 1 | 1999 | 99 | 0.030 |
Why?
|
| Incidence | 3 | 2016 | 1701 | 0.030 |
Why?
|
| Airway Resistance | 1 | 1997 | 68 | 0.030 |
Why?
|
| Fluorometry | 1 | 1997 | 30 | 0.030 |
Why?
|
| Registries | 2 | 2000 | 990 | 0.030 |
Why?
|
| Dilatation | 1 | 1997 | 47 | 0.030 |
Why?
|
| Pulmonary Edema | 1 | 1997 | 53 | 0.030 |
Why?
|
| Speech Disorders | 1 | 1996 | 17 | 0.030 |
Why?
|
| Speech Therapy | 1 | 1996 | 9 | 0.030 |
Why?
|
| Pharyngeal Neoplasms | 1 | 1996 | 15 | 0.030 |
Why?
|
| Reference Values | 1 | 1997 | 608 | 0.030 |
Why?
|
| Pharynx | 1 | 1996 | 44 | 0.030 |
Why?
|
| Everolimus | 1 | 2016 | 34 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1997 | 884 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 1995 | 17 | 0.030 |
Why?
|
| Heart Diseases | 1 | 1997 | 257 | 0.030 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 1994 | 17 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2014 | 22 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2014 | 53 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2014 | 45 | 0.030 |
Why?
|
| United States | 2 | 2017 | 7619 | 0.030 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 1993 | 19 | 0.030 |
Why?
|
| Cranial Nerves | 1 | 1993 | 7 | 0.030 |
Why?
|
| Photomicrography | 1 | 1993 | 7 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2004 | 161 | 0.030 |
Why?
|
| Gene Expression | 1 | 1997 | 1301 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2017 | 621 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 1998 | 442 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 192 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 338 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2014 | 3054 | 0.020 |
Why?
|
| Photosensitizing Agents | 1 | 1993 | 52 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2016 | 2440 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 1993 | 131 | 0.020 |
Why?
|
| Surgical Flaps | 1 | 1994 | 252 | 0.020 |
Why?
|
| Risk Factors | 2 | 2014 | 5898 | 0.020 |
Why?
|
| Fibrosis | 1 | 1993 | 230 | 0.020 |
Why?
|
| Carboplatin | 2 | 2003 | 322 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 624 | 0.020 |
Why?
|
| Organ Sparing Treatments | 1 | 2011 | 47 | 0.020 |
Why?
|
| Laser Therapy | 1 | 1993 | 151 | 0.020 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2011 | 39 | 0.020 |
Why?
|
| Recurrence | 1 | 1994 | 1190 | 0.020 |
Why?
|
| Retreatment | 1 | 2011 | 104 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2011 | 75 | 0.020 |
Why?
|
| Glutamates | 1 | 2011 | 84 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1993 | 454 | 0.020 |
Why?
|
| Guanine | 1 | 2011 | 194 | 0.020 |
Why?
|
| Deglutition Disorders | 1 | 2011 | 126 | 0.020 |
Why?
|
| Osteoradionecrosis | 1 | 2010 | 18 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2011 | 208 | 0.020 |
Why?
|
| Quality of Life | 3 | 2003 | 1780 | 0.020 |
Why?
|
| Deglutition | 1 | 2010 | 85 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2011 | 320 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 876 | 0.020 |
Why?
|
| Disease Progression | 2 | 2003 | 1531 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 985 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 1518 | 0.020 |
Why?
|
| Radiography | 2 | 1999 | 790 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 1999 | 3476 | 0.010 |
Why?
|
| Lymphatic Metastasis | 2 | 1998 | 504 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 181 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 225 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 3502 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 355 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2004 | 314 | 0.010 |
Why?
|
| Erythropoietin | 1 | 2003 | 90 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 512 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 1998 | 1338 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 1998 | 1799 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 829 | 0.010 |
Why?
|
| Hyperthyroidism | 1 | 2001 | 76 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 988 | 0.010 |
Why?
|
| Parathyroidectomy | 1 | 2001 | 79 | 0.010 |
Why?
|
| Thyroidectomy | 1 | 2001 | 173 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2001 | 401 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 1061 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2001 | 657 | 0.010 |
Why?
|
| Suppuration | 1 | 1999 | 8 | 0.010 |
Why?
|
| Illinois | 1 | 2001 | 520 | 0.010 |
Why?
|
| Laryngoscopy | 1 | 1999 | 50 | 0.010 |
Why?
|
| Tracheostomy | 1 | 1999 | 46 | 0.010 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 1998 | 14 | 0.010 |
Why?
|
| Mouth Floor | 1 | 1997 | 4 | 0.010 |
Why?
|
| Capillaries | 1 | 1998 | 83 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 1998 | 161 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1997 | 77 | 0.010 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 1998 | 57 | 0.010 |
Why?
|
| Microcirculation | 1 | 1997 | 98 | 0.010 |
Why?
|
| Mitosis | 1 | 1997 | 150 | 0.010 |
Why?
|
| Morbidity | 1 | 1997 | 162 | 0.010 |
Why?
|
| Carcinoma, Papillary | 1 | 1998 | 159 | 0.010 |
Why?
|
| Forecasting | 1 | 1997 | 293 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 1998 | 353 | 0.010 |
Why?
|
| Acute Disease | 1 | 1997 | 841 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1997 | 603 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1997 | 702 | 0.010 |
Why?
|
| Sex Factors | 1 | 1998 | 1105 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 1997 | 423 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1997 | 960 | 0.010 |
Why?
|
| Paraffin | 1 | 1993 | 4 | 0.010 |
Why?
|
| Age Factors | 1 | 1998 | 1906 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1993 | 158 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1993 | 218 | 0.010 |
Why?
|
| Adolescent | 1 | 2004 | 9606 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1997 | 1621 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 1998 | 1660 | 0.000 |
Why?
|